Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia. - Wikidata - wikimedia - TriplyDB

Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia.

Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia.

http://www.wikidata.org/entity/Q33706393

about

Guidelines on haemovigilance of post-transfusional iron overload Therapy-related myeloid neoplasms - what have we learned so far?Therapy-related myeloid neoplasms: pathobiology and clinical characteristics Allogeneic hematopoietic stem cell transplantation versus hypomethylating agents in patients with myelodysplastic syndrome: a retrospective case-control study Acute myeloid leukemia after myelodysplastic syndrome and failure of therapy with hypomethylating agents: an emerging entity with a poor prognosis.NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell Tr Anti-leukemia effect of ex vivo expanded DNT cells from AML patients: a potential novel autologous T-cell adoptive immunotherapy.Myelodysplastic syndrome evolving from aplastic anemia treated with immunosuppressive therapy: efficacy of hematopoietic stem cell transplantation Similar transplantation outcomes for acute myeloid leukemia and myelodysplastic syndrome patients with haploidentical versus 10/10 human leukocyte antigen-matched unrelated and related donors.Long-term health impacts of hematopoietic stem cell transplantation inform recommendations for follow-up.Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: a report on behalf of the MDS Clinical Research Consortium Altered hematopoietic cell gene expression precedes development of therapy-related myelodysplasia/acute myeloid leukemia and identifies patients at risk.Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and concurrent lymphoid malignancy.Subsequent malignant neoplasms after hematopoietic cell transplantation.Transplantation for myelodysplastic syndrome in the era of hypomethylating agents.Treatment-related myelodysplastic syndrome: molecular characteristics and therapy Myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation: diagnostic and therapeutic challenges Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS.Allogeneic hematopoietic cell transplantation for MDS: for whom, when and how?Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: the past decade.Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure.Review of stem-cell transplantation for myelodysplastic syndromes in older patients in the context of the Decision Memo for Allogeneic Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome emanating from the Centers for Medicare and M Acute myeloid leukemia and myelodysplastic syndromes after radiation therapy are similar to de novo disease and differ from other therapy-related myeloid neoplasms.Anti-thymocyte globulin (thymoglobulin), tacrolimus, and sirolimus as acute graft-versus-host disease prophylaxis for unrelated hematopoietic stem cell transplantation.Therapy-related myelodysplasia and acute myeloid leukemia The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia.Therapy-related myeloid neoplasms after autologous hematopoietic stem cell transplantation in lymphoma patients.The evolving challenge of therapy-related myeloid neoplasms.Transplantation for myelodysplastic syndromes 2013.MLL-Rearranged Leukemias-An Update on Science and Clinical Approaches.Minimal residual disease testing to predict relapse following transplant for AML and high-grade myelodysplastic syndromes.Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: current status.Immunotherapy in acute myeloid leukemia.Therapy-related myelodysplastic syndrome.Immunotherapy in acute myeloid leukemia.Secondary Adult Acute Myeloid Leukemia: a Review of Our Evolving Understanding of a Complex Disease Process.Reduced-intensity allogeneic stem cell transplantation for co-emergence of chemotherapy-refractory follicular lymphoma and therapy-related myelodysplastic syndrome Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel.Therapy-related myeloid neoplasms in patients treated for hodgkin lymphoma.Therapy-related Acute Myeloid Leukemia after the Long-term Administration of Low-dose Etoposide for Chronic-type Adult T-cell Leukemia-lymphoma: A Case Report and Literature Review.

P2860

Q27022721-87141B17-15EA-4DCD-9A98-9759EE0E8A10 Q28071318-63CFB3F5-B7B9-410D-B447-65B06DFE117B Q28386366-5C339DC7-7942-4027-92B6-0E82D9486D4E Q33856972-89043BE5-DEE4-4CCB-8CB9-AF18D4CF27FD Q33903024-34D53439-3A42-4A21-92FC-7BBDCAF44FC3 Q34044024-35F86F6C-B344-4AC9-8AD4-D56244E4BC03 Q34426965-FA8ACD4E-775B-4B0E-81EE-DF1801548544 Q34649014-7AF4F25A-63D6-4436-898E-121C703027D8 Q35129248-9002B785-CE93-443C-A934-CB18A2CE4CF4 Q35184667-D1470D87-34F3-45C3-8D93-6E46B8589BCD Q35230906-1D2F5348-4C2B-4BD9-89FD-2E21D5FB3FFC Q35563771-7E890BD4-872D-4222-BA17-2476DE76771B Q35613049-FF96D56D-B6F3-48F8-B4C2-5296B1F56B62 Q35678455-7EFEB3B1-16E7-490A-979D-4D9D55CDA809 Q35854094-39D4D987-04ED-4526-B017-E95BAE5AFA60 Q36219790-C751DCF9-4A22-4F56-834A-9B456C2DCEAD Q36266642-9557F15B-D95F-4D2F-9AAB-BB2B55413744 Q36339459-E9CE2ECC-1F48-47EB-AB89-059B7AD39283 Q36431041-5B91E4FF-64E5-4CF3-B788-39A35B3BE5A9 Q36811828-2B88C316-5EAE-4250-A6CD-D1DB48FD12FE Q36877036-80D728B5-6515-43D4-8BB4-23E1FA87AD27 Q36920394-F134356A-AB63-4C0C-A5E9-5A317EBE11C8 Q37163850-2E65B0AF-4C49-4FFB-A7FD-298C68AC543F Q37184046-ECDB6989-D2D5-45AD-9CFF-5ECFD35557E2 Q37402657-27C5237B-1777-4C32-801D-D4252359A012 Q37517482-28F48B38-DA04-41AD-9CB1-54C9AD4B67BF Q37548821-5CBC5E55-C907-4E00-B3DD-7B0C5CC4FC00 Q37576054-4B1917C5-4583-4CCC-A712-E5CB81C64F45 Q37600407-CD721784-1583-4CE3-97B2-7132A5E7D110 Q37633585-A880B36D-3D21-4FDD-B892-626FA649AD4C Q37872296-6B4A0E11-1410-4EA1-8832-45C17D9A5982 Q37964938-549F490A-315F-4AF5-A1E0-D8D3C3465223 Q38171574-A4A7AB25-8BE8-4135-9899-3E9F426664B4 Q38353167-C034A52F-1561-4C19-8FC0-523AADB97367 Q38533606-70645A98-0737-493F-ACDC-DC90510F6A02 Q38542828-B981AE31-620D-4AC9-979A-5333EF4D7628 Q38737930-902D4977-ED0C-497B-B57D-76B912152B59 Q39092515-506DF487-CEFE-491F-8BEA-6811D3FBA178 Q39209721-39391FEE-8A35-4BDF-A3AD-09C91FC2B884 Q39440364-B2843157-E1E4-4D2D-ADFA-5F2E5028E967

P2860

Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia.

http://www.wikidata.org/entity/Q33706393

description

2009 nî lūn-bûn

@nan

2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Allogeneic transplantation for ...... me and acute myeloid leukemia.

@ast

Allogeneic transplantation for ...... me and acute myeloid leukemia.

@en

type

label

Allogeneic transplantation for ...... me and acute myeloid leukemia.

@ast

Allogeneic transplantation for ...... me and acute myeloid leukemia.

@en

prefLabel

Allogeneic transplantation for ...... me and acute myeloid leukemia.

@ast

Allogeneic transplantation for ...... me and acute myeloid leukemia.

@en

P1433

Q33706393-3A3BD217-B0C8-4135-8D0C-D6466C12D967

P1476

Q33706393-7DB2A732-459A-477B-B4EA-096FF1A5CA10

P2093

Q33706393-024B6AFF-08D4-4E33-A362-74CC517EDA6E

Q33706393-2D80DF45-291E-4E76-950D-1AF9293F535F

Q33706393-3E124BC6-6BF0-4856-9029-598060D992DF

Q33706393-3FECE778-F1B8-450B-A378-69A25E0B95A7

Q33706393-578D811F-4D09-475C-B27E-6B5729DBEBF3

Q33706393-6261690F-4CA2-446D-9A34-49A5672F9DCD

Q33706393-6C51B735-0E1D-47B3-BF50-10596B89C912

Q33706393-827E23B3-4094-4D6E-9C68-059355CC1FDA

Q33706393-895A12B8-DE97-4D53-894E-57F4398B7C95

Q33706393-8E79E7E8-5463-43D8-8308-658DC97A34F3

P2860

Q33706393-05887791-FE04-4C8F-AC1E-F9A6AC19A0FF

Q33706393-08C18763-1DE9-4D25-B133-14FE08F39E0D

Q33706393-0ADEE438-BD2C-4389-BAFC-764E2DD0949E

Q33706393-0AF1427B-D99F-4FE9-B0A2-8D3B0F5EA39C

Q33706393-2E2DD89C-8F16-4BA5-AA48-5A19D707D173

Q33706393-3EDEC403-3B4F-4BA9-95B5-31A004C972B7

Q33706393-418DEA89-D269-4FB5-93B0-F8AD6B069AF5

Q33706393-5751DCE7-D9B2-4C90-89E4-63D1A29DA398

Q33706393-61B94396-99F6-4B0D-ADB2-04218FCC8287

Q33706393-6F6308AA-D2DE-4CD2-867D-B5E7FC74C924

P304

Q33706393-CBDB455C-0F93-4865-B046-0515B8D13658

P31

Q33706393-558BF5FD-21BA-4981-A36A-9BBCA9FA9520

P356

Q33706393-B47F1A17-6875-4ADC-9637-EB265002CAA5

P407

Q33706393-34244CF2-5530-4C72-9DF5-0D194B15D0DD

P433

Q33706393-6E620E03-B1FD-4082-B7A1-1CA36CD8D21A

P478

Q33706393-60C5823A-E560-4586-8013-3523E86F7D28

P50

Q33706393-C6C9A733-9C10-4D34-AA03-C7372284EF95

Q33706393-CC9AE7AA-870A-48A4-9430-A697A809B5C9

Q33706393-E502BFA7-5E3D-4B0A-91D4-A6ABE40B37B2

P577

Q33706393-54B3A528-6E68-49DA-957B-A5C8599A7C9D

P5875

Q33706393-2DCBD6AF-5FCD-4CB9-AC45-8BF47B6CA338

P698

Q33706393-CEFC0F61-0236-460C-831C-ADA4B2B85FE8

P921

Q33706393-1C220777-7E59-4C27-80BA-F0765315F867

P932

Q33706393-9CF9E1C0-C98C-42B9-A381-347D9C85D3D9

P356

BLOOD-2009-10-249128

P1433

P1476

Allogeneic transplantation for ...... me and acute myeloid leukemia.

@en

P2093

Armand Keating

http://www.w3.org/2001/XMLSchema#string

Brian J Bolwell

http://www.w3.org/2001/XMLSchema#string

Bruce M Camitta

http://www.w3.org/2001/XMLSchema#string

Corey S Cutler

http://www.w3.org/2001/XMLSchema#string

Daniel J Weisdorf

http://www.w3.org/2001/XMLSchema#string

David I Marks

http://www.w3.org/2001/XMLSchema#string

Gordon L Phillips

http://www.w3.org/2001/XMLSchema#string

J Douglas Rizzo

http://www.w3.org/2001/XMLSchema#string

John F Dipersio

http://www.w3.org/2001/XMLSchema#string

Jorge Sierra

http://www.w3.org/2001/XMLSchema#string

P2860

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study

The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties

International scoring system for evaluating prognosis in myelodysplastic syndromes

Evaluation of continuous infusion low-dose 5-azacytidine in the treatment of myelodysplastic syndromes.

Therapy-related acute myeloid leukemia and myelodysplasia after high-dose chemotherapy and autologous stem cell transplantation.

Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multicenter case-control study.

Does autologous transplantation directly increase the risk of secondary leukemia in lymphoma patients?

Therapy-related acute myelogenous leukemia and myelodysplastic syndrome.

Risk factors for therapy-related myelodysplastic syndrome and acute myeloid leukemia treated with allogeneic stem cell transplantation.

P304

1850-1857

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2009-10-249128

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

115

http://www.w3.org/2001/XMLSchema#string

P50

Robert Peter Gale

Martin S Tallman

Hillard M Lazarus

P577

2009-12-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

40767992

http://www.w3.org/2001/XMLSchema#string

P698

20032503

http://www.w3.org/2001/XMLSchema#string

P921

P932

2832815

http://www.w3.org/2001/XMLSchema#string